| A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study JJ Swen, CH van der Wouden, LEN Manson, H Abdullah-Koolmees, ... The Lancet 401 (10374), 347-356, 2023 | 173 | 2023 |
| Resveratrol in cancer patients: from bench to bedside M Berretta, A Bignucolo, R Di Francia, F Comello, G Facchini, ... International journal of molecular sciences 21 (8), 2945, 2020 | 78 | 2020 |
| Sex disparities in efficacy in COVID-19 vaccines: a systematic review and meta-analysis A Bignucolo, L Scarabel, S Mezzalira, J Polesel, E Cecchin, G Toffoli Vaccines 9 (8), 825, 2021 | 76 | 2021 |
| The Genotype for DPYD Risk Variants in Patients With Colorectal Cancer and the Related Toxicity Management Costs in Clinical Practice G Toffoli, F Innocenti, J Polesel, E De Mattia, F Sartor, C Dalle Fratte, ... Clinical Pharmacology & Therapeutics 105 (4), 994-1002, 2019 | 40 | 2019 |
| Pharmacogenomics of targeted agents for personalization of colorectal cancer treatment A Bignucolo, E De Mattia, E Cecchin, R Roncato, G Toffoli International journal of molecular sciences 18 (7), 1522, 2017 | 34 | 2017 |
| Genetic biomarkers for hepatocellular cancer risk in a caucasian population E De Mattia, E Cecchin, J Polesel, A Bignucolo, R Roncato, F Lupo, ... World journal of gastroenterology 23 (36), 6674, 2017 | 29 | 2017 |
| The multiple effects of vitamin D against chronic diseases: from reduction of lipid peroxidation to updated evidence from clinical studies M Berretta, V Quagliariello, A Bignucolo, S Facchini, N Maurea, ... Antioxidants 11 (6), 1090, 2022 | 25 | 2022 |
| Association of STAT-3 rs1053004 and VDR rs11574077 With FOLFIRI-Related Gastrointestinal Toxicity in Metastatic Colorectal Cancer Patients E De Mattia, E Cecchin, M Montico, A Labriet, C Guillemette, E Dreussi, ... Frontiers in Pharmacology 9, 367, 2018 | 19 | 2018 |
| FARMAPRICE: a pharmacogenetic clinical decision support system for precise and cost-effective therapy R Roncato, L Dal Cin, S Mezzalira, F Comello, E De Mattia, A Bignucolo, ... Genes 10 (4), 276, 2019 | 15 | 2019 |
| Germline polymorphisms in the nuclear receptors PXR and VDR as novel prognostic markers in metastatic colorectal cancer patients treated with FOLFIRI E De Mattia, J Polesel, R Roncato, A Labriet, A Bignucolo, E Dreussi, ... Frontiers in Oncology 9, 1312, 2019 | 14 | 2019 |
| Genetic markers of the host to predict the efficacy of colorectal cancer targeted therapy E De Mattia, A Bignucolo, G Toffoli, E Cecchin Current Medicinal Chemistry 27 (25), 4249-4273, 2020 | 13 | 2020 |
| Evaluation of concomitant use of anticancer drugs and herbal products: From interactions to Synergic Activity M Berretta, L Dal Lago, M Tinazzi, A Ronchi, G La Rocca, L Montella, ... Cancers 14 (21), 5203, 2022 | 12 | 2022 |
| IL15RA and SMAD3 genetic variants predict overall survival in metastatic colorectal cancer patients treated with folfiri therapy: A new paradigm E De Mattia, J Polesel, R Roncato, A Labriet, A Bignucolo, S Gagno, ... Cancers 13 (7), 1705, 2021 | 11 | 2021 |
| DPYD gene activity score predicts dose-limiting toxicity in fluoropyrimidine-treated colorectal cancer patients P Jerry, R Rossana, E Fabrizio, B Alessia, G Marica, D Eva, P Elisa, ... Journal of Molecular and Clinical Medicine 1 (3), 143-150, 2018 | 10 | 2018 |
| Assessment of pharmacogenomic SLCO1B1 assay for prediction of neuromuscular pain in type 2 diabetes mellitus and cardiovascular patients: preliminary results. A Licito, G Marotta, M Battaglia, G Benincasa, L Mentone, MR Grillo, ... European Review for Medical & Pharmacological Sciences 24 (1), 2020 | 8 | 2020 |
| Ten-year experience with pharmacogenetic testing for DPYD in a national cancer center in Italy: Lessons learned on the path to implementation A Bignucolo, E De Mattia, R Roncato, E Peruzzi, L Scarabel, M D’Andrea, ... Frontiers in Pharmacology 14, 1199462, 2023 | 7 | 2023 |
| SMAD3 host and tumor profiling to identify locally advanced rectal cancer patients at high risk of poor response to neoadjuvant chemoradiotherapy E De Mattia, V Canzonieri, J Polesel, S Mezzalira, C Dalle Fratte, ... Frontiers in Pharmacology 12, 778781, 2021 | 4 | 2021 |
| Cost-utility analysis and cross-country comparison of pharmacogenomics-guided treatment in colorectal cancer patients participating in the U-PGx PREPARE study V Fragoulakis, R Roncato, A Bignucolo, GP Patrinos, G Toffoli, E Cecchin, ... Pharmacological Research 197, 106949, 2023 | 3 | 2023 |
| Implementation of pre‐emptive testing of a pharmacogenomic panel in clinical practice: Where do we stand? E Peruzzi, R Roncato, E De Mattia, A Bignucolo, JJ Swen, HJ Guchelaar, ... British Journal of Clinical Pharmacology, 2023 | 2 | 2023 |
| LC-MS/MS method for the quantification of PARP inhibitors olaparib, rucaparib and niraparib in human plasma and dried blood spot: Development, validation and clinical … G Canil, M Orleni, B Posocco, S Gagno, A Bignucolo, M Montico, ... Pharmaceutics 15 (5), 1524, 2023 | 2 | 2023 |
Elena De MattiaExperimental and Clinical Pharmacology, Centro di Riferimento Oncologico- National Cancer Institute, Aviano, ItalyEmail verificata su cro.it
